Organovo Holdings plans to price public offering of its common shares

Joint bookrunners Lazard Capital and Oppenheimer assist with offering

By Devika Patel

Knoxville, Tenn., Aug. 1 - Organovo Holdings, Inc. plans to price a public offering of common stock with a 30-day greenshoe, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission.

Lazard Capital Markets and Oppenheimer & Co are the joint bookrunners.

Proceeds will be used for debt repayment and for general corporate purposes, including research and development, product development and commercialization, general administrative expenses, license or technology acquisitions, working capital and capital expenditures.

Based in San Diego, Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.